EMA/184300/2023

European Medicines Agency decision

P/0187/2023

of 15 May 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atrasentan (EMEA-001666-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0187/2023

of 15 May 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for atrasentan (EMEA-001666-PIP02-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Chinook Therapeutics, Inc. on 20 December 2021 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 March 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for atrasentan, film-coated tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for atrasentan, film-coated tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for atrasentan, film-coated tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Chinook Therapeutics, Inc., 400 Fairview Ave. North, Suite 900, 98109 – Seattle, United States.

EMA/PDCO/7773/2023
Amsterdam, 31 March 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001666-PIP02-21

Scope of the application

Active substance(s):

Atrasentan

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of IgA nephropathy

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Chinook Therapeutics, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Chinook Therapeutics, Inc. submitted for agreement to the European Medicines Agency on 20 December 2021 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 31 January 2022.

Supplementary information was provided by the applicant on 16 December 2022. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of IgA nephropathy

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- film-coated tablet, age-appropriate oral formulation, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of IgA nephropathy

2.1.1. Indication(s) targeted by the PIP

Treatment of children with IgA nephropathy at high risk for progression of kidney function decline, who are on a stable dose of, or are refractory or intolerant to renin-angiotensin system (RAS) inhibitors

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet, age-appropriate oral formulation

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Development of an age-appropriate oral formulation
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Open-label, non-comparative trial to evaluate pharmacokinetics, safety and efficacy of atrasentan in subjects from 2 years to less than 18 years of age with IgA nephropathy

Modelling and simulation studies	**Study 3** Modelling and simulation study to evaluate the use of atrasentan in children and adolescents from 2 years to less than 18 years of age with IgA nephropathy
Other studies	Not applicable
Extrapolation plan	Studies 2 and 3 are part of an extrapolation plan covering the paediatric population from 2 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.